Alpha Beta Test
As you move along the R&D pathway from early asset development to clinical trial submission, your testing methodology can hold things up – whether that’s poor efficacy translation from small animal models, adverse effects or simply a resource issue.
At Pebble, we’ve developed LIVING-ORGAN systems, a unique ex vivo organ perfusion model: superior to in vitro and rodent models thanks to comparable human physiology, and more ethical due to a complete absence of laboratory animals.
With our Alpha-Beta Test, we take you from early testing to clinical trial in less time, at lower costs and with better results.


Why Choose Pebble?
When you decide to work with us you get access to all the benefits of the ALPHA-BETA Test model and our LIVING-ORGAN systems.
The ALPHA Test rapidly iterates your therapy without having to include the data in regulatory submissions.
The BETA Test phase brings in the power of our LIVING-ORGAN systems to generate detailed and robust submission-ready data packs tailored to meet regulatory authority requirements.

Enhanced Efficiency
Your R&D process is streamlined, saving you time & resources.

Iterative Refinement
We identify & solve major issues early on to mitigate risk & delays.

Regulatory Success
We work closely with you to generate data tailored to regulatory requirements, easing the path to clinical trial approval.

Ethical
LIVING-ORGAN systems does not use laboratory animals – all material is surplus biological material from the food industry.

Cost Saving
The complete lack of laboratory animals significantly reduces costs – that’s roughly an 80% cost-saving compared to large animal in vivo experiments.

Time Saving
Your study can be started in days and completed in weeks, rather than months or years.

Expertise
We’re led by James Fildes, CEO & CSO, and a Professor of Experimental Surgery. We’re supported by scientists with years of expertise in perfusion, clinical surgery, immunology & data analysis.